133 related articles for article (PubMed ID: 38182100)
1. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E; Haufroid V; Deldicque L; Balligand JL; Elens L
Clin Biochem; 2024 Feb; 124():110707. PubMed ID: 38182100
[TBL] [Abstract][Full Text] [Related]
2. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites.
Turner RM; Fontana V; Zhang JE; Carr D; Yin P; FitzGerald R; Morris AP; Pirmohamed M
Clin Pharmacol Ther; 2020 Aug; 108(2):287-297. PubMed ID: 32128760
[TBL] [Abstract][Full Text] [Related]
3. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
4. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
5. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
6. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
8. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
[TBL] [Abstract][Full Text] [Related]
9. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
[TBL] [Abstract][Full Text] [Related]
11. The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
León-Cachón RBR; Bamford AD; Meester I; Barrera-Saldaña HA; Gómez-Silva M; Bustos MFG
Sci Rep; 2020 Jun; 10(1):8900. PubMed ID: 32483134
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms.
Lauritzen T; Munkhaugen J; Peersen K; Kristiansen O; Sverre E; Nebauer SD; Villseth M; Andersen AM; Svarstad AC; Jensen EP; Bergan S; Husebye E; Vethe NT
Clin Pharmacol Ther; 2023 Apr; 113(4):887-895. PubMed ID: 36622792
[TBL] [Abstract][Full Text] [Related]
13. Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines.
Hoste E; Paquot A; Panin N; Horion S; El Hamdaoui H; Muccioli GG; Haufroid V; Elens L
Ther Drug Monit; 2023 Jun; 45(3):400-408. PubMed ID: 36253893
[TBL] [Abstract][Full Text] [Related]
14. Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis.
Du Y; Wang S; Chen Z; Sun S; Zhao Z; Li X
Curr Pharm Des; 2018; 24(34):4044-4050. PubMed ID: 30569848
[TBL] [Abstract][Full Text] [Related]
15. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.
Bakar NS; Neely D; Avery P; Brown C; Daly AK; Kamali F
Clin Pharmacol Ther; 2018 Jul; 104(1):178-187. PubMed ID: 28940218
[TBL] [Abstract][Full Text] [Related]
16. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
[TBL] [Abstract][Full Text] [Related]
18. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
[TBL] [Abstract][Full Text] [Related]
19. The effect of
Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
[TBL] [Abstract][Full Text] [Related]
20. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
